157 related articles for article (PubMed ID: 38602320)
1. The HLA-I landscape confers prognosis and antitumor immunity in breast cancer.
Ding XH; Xiao Y; Chen F; Liu CL; Fu T; Shao ZM; Jiang YZ
Brief Bioinform; 2024 Mar; 25(3):. PubMed ID: 38602320
[TBL] [Abstract][Full Text] [Related]
2. Integrated analysis reveals prognostic value of HLA-I LOH in triple-negative breast cancer.
Zhou YF; Xiao Y; Jin X; Di GH; Jiang YZ; Shao ZM
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34615706
[TBL] [Abstract][Full Text] [Related]
3. Association Between Genomic Metrics and Immune Infiltration in Triple-Negative Breast Cancer.
Karn T; Jiang T; Hatzis C; Sänger N; El-Balat A; Rody A; Holtrich U; Becker S; Bianchini G; Pusztai L
JAMA Oncol; 2017 Dec; 3(12):1707-1711. PubMed ID: 28750120
[TBL] [Abstract][Full Text] [Related]
4. Germline HLA-B evolutionary divergence influences the efficacy of immune checkpoint blockade therapy in gastrointestinal cancer.
Lu Z; Chen H; Jiao X; Wang Y; Wu L; Sun H; Li S; Gong J; Li J; Zou J; Yang K; Hu Y; Mao B; Zhang L; Zhang X; Peng Z; Lu M; Wang Z; Zhang H; Shen L
Genome Med; 2021 Nov; 13(1):175. PubMed ID: 34732240
[TBL] [Abstract][Full Text] [Related]
5. Divergent HLA variations and heterogeneous expression but recurrent HLA loss-of- heterozygosity and common
Lim WC; Marques Da Costa ME; Godefroy K; Jacquet E; Gragert L; Rondof W; Marchais A; Nhiri N; Dalfovo D; Viard M; Labaied N; Khan AM; Dessen P; Romanel A; Pasqualini C; Schleiermacher G; Carrington M; Zitvogel L; Scoazec JY; Geoerger B; Salmon J
Front Immunol; 2023; 14():1265469. PubMed ID: 38318504
[TBL] [Abstract][Full Text] [Related]
6. MxA expression is associated with tumor-infiltrating lymphocytes and is a prognostic factor in triple-negative breast cancer.
Kim YA; Lee HJ; Heo SH; Park HS; Park SY; Bang W; Song IH; Park IA; Gong G
Breast Cancer Res Treat; 2016 Apr; 156(3):597-606. PubMed ID: 27075916
[TBL] [Abstract][Full Text] [Related]
7. Genomic and Transcriptomic Landscape of Triple-Negative Breast Cancers: Subtypes and Treatment Strategies.
Jiang YZ; Ma D; Suo C; Shi J; Xue M; Hu X; Xiao Y; Yu KD; Liu YR; Yu Y; Zheng Y; Li X; Zhang C; Hu P; Zhang J; Hua Q; Zhang J; Hou W; Ren L; Bao D; Li B; Yang J; Yao L; Zuo WJ; Zhao S; Gong Y; Ren YX; Zhao YX; Yang YS; Niu Z; Cao ZG; Stover DG; Verschraegen C; Kaklamani V; Daemen A; Benson JR; Takabe K; Bai F; Li DQ; Wang P; Shi L; Huang W; Shao ZM
Cancer Cell; 2019 Mar; 35(3):428-440.e5. PubMed ID: 30853353
[TBL] [Abstract][Full Text] [Related]
8. Loss of Human Leukocyte Antigen and Immune Escape in Head and Neck Cancer.
Morris LGT
Laryngoscope; 2024 Jan; 134(1):160-165. PubMed ID: 37249223
[TBL] [Abstract][Full Text] [Related]
9. PD-L1 and CD8 are associated with deficient mismatch repair status in triple-negative and HER2-positive breast cancers.
Hou Y; Nitta H; Parwani AV; Li Z
Hum Pathol; 2019 Apr; 86():108-114. PubMed ID: 30633926
[TBL] [Abstract][Full Text] [Related]
10. Differential expression of major histocompatibility complex class I in subtypes of breast cancer is associated with estrogen receptor and interferon signaling.
Lee HJ; Song IH; Park IA; Heo SH; Kim YA; Ahn JH; Gong G
Oncotarget; 2016 May; 7(21):30119-32. PubMed ID: 27121061
[TBL] [Abstract][Full Text] [Related]
11. HLA class I alterations in breast carcinoma are associated with a high frequency of the loss of heterozygosity at chromosomes 6 and 15.
Garrido MA; Rodriguez T; Zinchenko S; Maleno I; Ruiz-Cabello F; Concha Á; Olea N; Garrido F; Aptsiauri N
Immunogenetics; 2018 Nov; 70(10):647-659. PubMed ID: 30145665
[TBL] [Abstract][Full Text] [Related]
12. Homologous recombination deficiency and host anti-tumor immunity in triple-negative breast cancer.
Telli ML; Stover DG; Loi S; Aparicio S; Carey LA; Domchek SM; Newman L; Sledge GW; Winer EP
Breast Cancer Res Treat; 2018 Aug; 171(1):21-31. PubMed ID: 29736741
[TBL] [Abstract][Full Text] [Related]
13. Integrated molecular profiling of young and elderly patients with triple-negative breast cancer indicates different biological bases and clinical management strategies.
Ma D; Jiang YZ; Xiao Y; Xie MD; Zhao S; Jin X; Xu XE; Shao ZM
Cancer; 2020 Jul; 126(14):3209-3218. PubMed ID: 32383785
[TBL] [Abstract][Full Text] [Related]
14. Less correlation between mismatch repair proteins deficiency and decreased expression of HLA class I molecules in endometrial carcinoma: a different propensity from colorectal cancer.
Mariya T; Kubo T; Hirohashi Y; Yanagawa J; Tabuchi Y; Matsuo K; Furumura K; Morita R; Nakatsugawa M; Kanaseki T; Tsukahara T; Hasegawa T; Saito T; Torigoe T
Med Mol Morphol; 2021 Mar; 54(1):14-22. PubMed ID: 32410009
[TBL] [Abstract][Full Text] [Related]
15. STAT3-induced HLA-F-AS1 promotes cell proliferation and stemness characteristics in triple negative breast cancer cells by upregulating TRABD.
Wu D; Jia H; Zhang Z; Li S
Bioorg Chem; 2021 Apr; 109():104722. PubMed ID: 33618253
[TBL] [Abstract][Full Text] [Related]
16. Expression of HLA class I is associated with immune cell infiltration and patient outcome in breast cancer.
Han SH; Kim M; Chung YR; Woo JW; Choi HY; Park SY
Sci Rep; 2022 Nov; 12(1):20367. PubMed ID: 36437379
[TBL] [Abstract][Full Text] [Related]
17. Molecular Subtyping of Triple-Negative Breast Cancers by Immunohistochemistry: Molecular Basis and Clinical Relevance.
Zhao S; Ma D; Xiao Y; Li XM; Ma JL; Zhang H; Xu XL; Lv H; Jiang WH; Yang WT; Jiang YZ; Zhang QY; Shao ZM
Oncologist; 2020 Oct; 25(10):e1481-e1491. PubMed ID: 32406563
[TBL] [Abstract][Full Text] [Related]
18. Prognostic and Clinical Significance of Human Leukocyte Antigen Class I Expression in Breast Cancer: A Meta-Analysis.
Qiao W; Jia Z; Guo W; Liu Q; Guo X; Deng M
Mol Diagn Ther; 2023 Sep; 27(5):573-582. PubMed ID: 37464212
[TBL] [Abstract][Full Text] [Related]
19. Targeting the Molecular Subtypes of Triple Negative Breast Cancer: Understanding the Diversity to Progress the Field.
Yam C; Mani SA; Moulder SL
Oncologist; 2017 Sep; 22(9):1086-1093. PubMed ID: 28559413
[TBL] [Abstract][Full Text] [Related]
20. Genomic regulation of invasion by STAT3 in triple negative breast cancer.
McDaniel JM; Varley KE; Gertz J; Savic DS; Roberts BS; Bailey SK; Shevde LA; Ramaker RC; Lasseigne BN; Kirby MK; Newberry KM; Partridge EC; Jones AL; Boone B; Levy SE; Oliver PG; Sexton KC; Grizzle WE; Forero A; Buchsbaum DJ; Cooper SJ; Myers RM
Oncotarget; 2017 Jan; 8(5):8226-8238. PubMed ID: 28030809
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
